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Abstract
The ability of clinicians to wage an effective war against many bacterial infections is increasingly
being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a
significant problem for treatment of diseases caused by virtually all known infectious bacteria. The
gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the
world’s population infected, H. pylori exacts a tremendous medical burden and represents an
interesting paradigm for cancer development; it is the only bacterium that is currently recognized
as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases
such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric
adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large
percentage of the population infected, increasing rates of antibiotic resistance are particularly
vexing for a treatment regime that is already fairly complicated; treatment consists of two
antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and
secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
The war between antibiotics and bacteria
The knowledge that bacteria were susceptible to antibiotics had its genesis in1877 with he
first report by Pasteur and Joubert that a bacterium produced a toxic substance that killed
other bacteria (cited in [1]). Fifty-two years later, penicillin was identified in 1929 as an
antimicrobial by Fleming [2]. After it was shown that penicillin was able to prevent a lethal
infection of streptococcus in mice [3] and to treat human disease [4, 5], it was thought that
antibiotics would easily eliminate infectious disease. However, to everyone’s surprise,
bacteria are strategic fighters, and have adapted to become resistant to a multitude of
antibiotics used to treat infection. Because of this, it is no exaggeration to say that, on some
fronts, bacteria are on the verge of winning the war.
Broadly defined, antibiotics are either natural or synthetic products that kill (bactericidal) or
inhibit growth (bacteriostatic) of bacteria. Antibiotics must be selectively toxic for the
microbe, and current drug classes target four key aspects of bacterial growth and physiology.
The targets include bacterial cell wall synthesis, foliate coenzyme synthesis, protein
synthesis, and nucleic acid (DNA or RNA) synthesis [6]. Bacterial antibiotic resistance
mechanisms can similarly be broken into five major classes. These include alteration of the
antibiotic target, enzymatic destruction of the antibiotic, enzymatic modification of the
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antibiotic, decreased permeability of the antibiotic, and increased efflux of the antibiotic
from the bacterial cell (Table 1) [6].
Introduction of the enemy: Helicobacter pylori
Helicobacter pylori was first isolated from patients suffering from chronic gastritis in 1982
[7]. H. pylori is a Gram-negative, spiral shaped bacterium that colonizes the arguably
inhospitable niche of the stomach, and persists for the lifetime of the host, if untreated [8].
Additionally, H. pylori causes a wide range of diseases. This organism is associated with
gastritis, 90% of all duodenal ulcers, 75% of all gastric ulcers [9], and two forms of stomach
cancer, adenocarcinoma and MALT lymphoma [9–12]. Though infection rates show wide
geographic distribution, this strategic bacterium chronically colonizes over 50% of the
world’s population [13]. The high incidence of H. pylori infection likely contributes to the
fact that gastric cancer mortality ranks second among all cancer deaths worldwide [14]. Due
to the causal relationship between H. pylori and gastric malignancies, the World Health
Organization classified H. pylori as a Class I carcinogen in 1994 [15]. Currently, H. pylori is
the only bacterium to have achieved this perilous distinction.
During the relatively short period of time that we have known about H. pylori, there have
been many different treatment regimens developed (reviewed in [16]. In fact, in 1994 there
was a consensus from the National Institute of Health (USA) [17], followed two years later
by the Maastricht Consensus from the European Helicobacter Study Group (Netherlands)
[18], which established treatment recommendations to treat H. pylori infection. Given the
increase in incidence of antibiotic resistance, the Maastricht Consensus report was updated
in 2000 and again in 2005 to increase the effectiveness of treatment regimens against H.
pylori [19, 20].
The current recommendation for first line therapy in locations where clarithromycin
resistance is low, is a protein pump inhibitor, clarithromycin, and either metronidazole (first
choice) or amoxicillin (second choice) for 14 days [20]. Additionally, these triple therapy
regimens can be supplemented by the addition of bismuth in geographical areas where
antibiotic resistance is high, though this combination is typically recommended as a second
line therapy [20]. Moreover, since bismuth is not available in many countries, a combination
of a proton pump inhibitor, metronidazole, and either amoxicillin or tetracycline is
sometimes recommended [20].
Primary and secondary therapies are not always successful at eradicating H. pylori;
therefore, there are many alternative drugs that are proposed for rescue therapy. These
include fluoroquinolones (such as levofloxacin), rifamycins (such as rifabutin and
rifampicin), nitrofurans (such as furazolidone) and other members (such as doxycycline)
within families that are already used to treat H. pylori infection (reviewed in [16, 21]. Of
note, resistance has been found to all utilized primary and secondary antibiotics, as well as,
to many of the antimicrobials used for rescue therapy. This fact suggests that therapy
success rates will continue to decline, and indicates that a detailed understanding of
antibiotic resistance mechanisms may facilitate development of novel therapeutics. As such,
the molecular mechanisms of H. pylori antimicrobial resistance are discussed in detail in this
review (Table 2 and Figure 1).
First Line Therapy and Resistance
Macrolides (primarily clarithromycin)—Clarithromycin is one of the first line therapy
antibiotics used against H. pylori and is part of a class of broad spectrum antibiotics called
macrolides [20]. Macrolides function to prevent protein translation. Specifically, these
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antibiotics interact with the bacterial ribosome and promote the premature release of
peptidyl-tRNA from the acceptor site [22, 23].
Macrolide resistant H. pylori strains have been shown to be selected for during the course of
treatment [24]. Moreover, clarithromycin resistance has been pinpointed to nucleotide
mutations, the majority of which are single nucleotide mutations, in one of the two
macrolide binding domains of the 23S rRNA [25, 26]. Most significant mutations are
contained in Domain V of the 23S rRNA. In fact, this mechanism of clarithromycin
resistance in H. pylori was first described in 1996 by Versalovic et al. Since the
nomenclature for these mutations is confusing due to variation in the length of the 23S
rRNA gene among strains, for this review we will employ the nomenclature for the 23S
rRNA gene published by Taylor et al. [27]. At first, single nucleotide substitutions of an
adenine to guanine at nucleotide positions 2142 (A2142G) and 2143 (A2143G), of the 23S
rRNA were discovered [22]. Subsequently these same mutations were found in several other
clarithromycin resistant strains [22, 24, 27–32]. Additional evidence that mutations within
this domain are important for macrolide resistance in H. pylori came with the discovery that
a transversion of an adenine to cytosine at position 2142 (A2142C) also conferred
clarithromycin resistance [33]. In some studies as many as 91.4% of clarithromycin resistant
strains contain the A2142G or the A2143G mutation [30]. Moreover, these are the
predominant mutations found in Brazil [34], France [35], and Spain [36].
Other mutations within domain V of the 23S rRNA that have been identified to confer
macrolide resistance include T2182C [37], A2144T [38], G2223A, C2244T, and T2288C
[39], though the ability of the T2182C mutation to confer macrolide resistance remains in
question, due to the fact that this mutation has been found in both resistant and sensitive
strains [40]. The double mutation of A2115G and G2141A has also been demonstrated to
confer resistance [29, 41].
Other important clarithromycin resistance mutations lay outside of domain V of the 23S
rRNA. One such mutation, T2717C, results in low level clarithromycin resistance [42].
Additionally, other clarithromycin resistant H. pylori strains contain no mutations in the 23S
rRNA [28, 42]. Though the exact mechanism remains undefined, this fact indicates another
means of obtaining macrolide resistance. In other bacteria, macrolide resistance can occur
through methylation of a specific adenine on the 23S rRNA [25, 43, 44]. This is achieved
through the presence of rRNA methylases, termed erm genes (erythromycin resistance
methylase) [43]. Despite the presence of clarithromycin resistance that is not associated with
mutations of the 23S rRNA, scientists have failed to clone a single erythromycin resistance
determinant from any H. pylori resistant isolate tested, and have failed to find genes with
homology to any previously reported erm genes [29]. This has left the nature of this
resistance in question. Interestingly, H. pylori has the ability to remove a different
macrolide, erythromycin, via the HefABC efflux pump; however, H. pylori cannot efflux
clarithromycin through this pump [45]. Based on the studies described above, it is clear that
continued treatment of H. pylori with clarithromycin will likely lead to increasing rates of
resistance, and may lead to resistance to multiple macrolides due to cross-resistance [29].
Beta-lactams (amoxicillin)—β-lactams are one of the best weapons clinicians have
against H. pylori. The β-lactam antibiotics are subdivided into 5 groups. These include
penicillins, cephalosporins, carbapenems, monobactams, and clavams [6]. All β-lactam
antibiotics inhibit synthesis of the peptidoglycan layer of the bacterial cell wall. They do so
by targeting penicillin binding proteins (PBPs) on the cytoplasmic membrane [46]. These
PBPs are enzymes that carry out carboxypeptidation and transpeptidation, which are the
terminal steps of peptidoglycan biosynthesis [46–48]. Broadly speaking, in other bacteria
resistance to β-lactams arises by decreased membrane permeability of the drugs, increased
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efflux of the drug from the bacterial cell, modification of the PBPs that diminish the affinity
of the drug for the protein, and the presence of β-lactamases that inactivate the antibiotic by
hydrolyzing its ring structure [6].
Amoxicillin is a semi-synthetic penicillin that is currently the only β-lactam used to treat H.
pylori infection. While initial treatment with amoxicillin suggested that it was very effective,
amoxicillin resistance was documented in 1998, when the Hardenberg strain was isolated in
Holland from an 82 year old dyspeptic patient [49]. Currently, amoxicillin resistance rates
vary from as low as 0% to as high as 59% [50–53].
H. pylori contains nine putative penicillin binding proteins [54–56]. Of these, mutations of
PBP1 [57–62] and PBP4 (also known as PBPD) [54, 55] have been shown to impact
amoxicillin resistance. In terms of PBP4, a decreased amount of this protein was
demonstrated to confer low level resistance to amoxicillin [55]. In fact, other resistant strains
were confirmed to have no detectable PBP4 [54, 55].
In contrast, amino acid mutations in PBP1 can result in resistance due to decreased affinity
for amoxicillin [57]. Studies have shown that most amino acid substitutions that result in
resistance occur in the carboxy terminus of PBP1 in the penicillin binding domain [63]. For
instance, PBP1 from the Hardenberg strain contains a single amino acid substitution of
serine to arginine at position 414 (Ser414Arg) [58, 63]. Interestingly, Kwon et al. deduced
that β-lactam resistance was acquired with multidrug resistance, and that 10 different amino
acid substations in the PBP1 penicillin binding domain could confer resistance: Glu406Ala,
Ser417Thr, Met515Ile, Asp535Asn, Ser543Arg, Thr556Ser, Asn562Tyr, Lys648Gln,
Arg649Lys, and Arg656Pro [59]. Two of the previously described amino acid mutations
(Thr556Ser [63, 64] and Asn562Tyr [63] were later confirmed, and additional amino acid
mutations conferring resistance were identified; Ala369Thr, Val374Leu, Leu423Phe,
Thr593Ala, and Gly595Ser [63]. Additionally, an in vitro study found that Thr438Met
mutation is sufficient to cause resistance [60]. Another study showed that a nonsense
mutation in the 3′ end was enough to confer resistance [64].
While mutations in PBP2 (ftsI) and PBP3 (pbp2) alone are enough to confer resistance to
other β-lactams (ceftriaxone and ceftazidime), no mutations within either of these genes
individually conferred resistance to amoxicillin [65]. However, combined mutations in
PBP1 (Ser414Arg, Leu423Phe, Asn562Try, and Thr593Ala) and PBP3 (Ala499Val and
Glu536Lys) yielded a higher level of resistance to amoxicillin [65]. Interestingly, even
though mutations in PBP2 alone or in combination with mutations in PBP1 did not yield or
increase amoxicillin resistance, respectively, the combination of mutations in PBP2
(Ala296Val, Asn/Ser494His, Ala/Val541Met, and Glu572Gly) worked synergistically with
the aforementioned mutations found in PBP1 and PBP3 to confer an even greater level of
amoxicillin resistance [65].
In addition to decreased amoxicillin binding [57], resistance can also result from mutations
that decrease membrane permeability of the drug [47, 59, 61]. Mutations in two different
outer membrane proteins have been proven to be sufficient to cause amoxicillin resistance
[60]. These mutations include changes in amino acids 116–201 of hopB or a stop codon at
amino acid 211 of hopC [60].
Nitroimidazoles, primarily metronidazole
Nitroimidazoles are synthesized as inactive prodrugs and require reduction inside the
bacteria by specific non-human reductases to become active [66, 67]. In their active forms,
nitroimidazoles produce toxic intermediates that result in DNA damage that kills the
bacteria [66]. Metronidazole is a nitroimidazole that was efficiently used to treat H. pylori
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infection. However, H. pylori has adapted to be able to strategically escape the effectiveness
of metronidazole treatment. Metronidazole resistance rates vary from 29–52% [68, 69] in
some regions, and are as high as 100% in certain places [70].
The mechanism for metronidazole resistance in H. pylori is probably the most studied and
most controversial topic concerning antibiotic resistance in the H. pylori field. Early studies
showed that resistant strains accumulated metronidazole at a slower rate and to a lesser
extent than sensitive strains, suggesting a role for transporters or efflux systems in resistance
[71]. Other work suggested that mutations in recA might be responsible for resistance [72],
but later studies found no evidence that mutations in recA lead to metronidazole resistance
[73].
The first real breakthrough in understanding metronidazole resistance came with the
discovery that resistant bacteria reduce other 5-nitroimidazole compounds more slowly than
sensitive strains [74]. This indicated that resistance is a product of lack of reduction of the
prodrugs [74]. Goodwin et al. showed that metronidazole’s toxicity depends on its reduction
by the oxygen-insensitive, nicotinamide adenine dinucleotide phosphate (NADPH)
nitroreductase (rdxA), and that resistance arises from mutations that inactivate rdxA [75].
Specifically, a nonsense mutation caused the truncation of 14 amino acids, and other point
mutations (both nonsense and missense) were found elsewhere in the rdxA gene [75].
Many other studies have identified specific mutations in rdxA that result in metronidazole
resistance [73, 76–78]. The majority of these mutations result in a truncated RdxA protein
[79–81]. Other resistant isolates have been identified that encode full length RdxA, but
contain amino acid substitutions (Arg16His, Ala80Thr, Ala118Ser, Gln197Lys, Val204Ile
[80], Tyr46His, Pro51Leu, Ala67Val [79], and Cys19Tyr [77]).
While inactivation of rdxA clearly causes metronidazole resistance, the association of
specific amino acid mutations with resistance remains controversial, since very few studies
made specific rdxA amino acid substitutions and then tested for resistance. Instead, resistant
strains are often identified, and then rdxA is simply sequenced to identify changes and any
differences are ascribed to impart metronidazole resistance, without distinguishing
resistance-associated nucleotide mutations from natural genetic diversity. However, newer
studies show that the majority of rdxA sequences were identical between susceptible and
resistant strains, leading the authors to suggest that inactivation of RdxA is sufficient but not
essential to obtain metronidazole resistance [78, 82]. This evidence, coupled with the fact
that some resistant strains do not have mutations within the rdxA gene [76, 79, 83], suggests
that other resistance mechanisms exist in H. pylori.
Kwon et al. were the first to discover that mutations in the NADPH flavin oxidoreductase
gene (frxA) conferred metronidazole resistance [84]. Deletion mutations resulting in
truncations of the frxA gene confer metronidazole resistance [84, 85], and missense
mutations in frxA (Cys161Tyr, Arg206His, and a double mutation of Trp137Arg and
Glu164Gly), without specific changes in rdxA, confer low level resistance [85]. High
metronidazole resistance is conferred when both the frxA and rdxA genes are prematurely
truncated, indicating a synergistic effect on resistance [77, 83–85]. In contrast to these
studies, others have found that frxA inactivation does not significantly change susceptibility
to metronidazole [86]. Also, the majority of resistant strains with mutations in frxA also have
mutations in rdxA [87], and truncations of frxA have been identified in metronidazole
sensitive H. pylori isolates [88]. These facts, combined with work that suggested that
inactivation of frxA in a strain with a functional rdxA only slowed the bactericidal effects of
metronidazole [87], has led some to suggest that a frxA mutation alone may not be enough to
impart resistance [89].
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Another controversy in the metronidazole field lies in the debate as to whether other genes
besides rdxA and frxA may have a role in metronidazole resistance. Some metronidazole
resistant isolates have functional rdxA and frxA with no identified mutations, indicating that
there are other mechanisms leading to metronidazole resistance [90]. One area of study has
focused on the roll of various Helicobacter pylori reductases in metronidazole resistance. It
was found that disruption of the fdxB (ferredoxin-like protein) nitroreductase resulted in an
increased level of metronidazole resistance in strains with an inactivated rdxA [83]. Other
reductases, such as alkyl hydroperoxide reductase, AhpC [91], have been suggested to play a
role in resistance since the expression levels of various isoforms of ahpC are increased when
resistant strains are grown in the presence of metronidazole [92]. While thioredoxin
reductase has been found to reduce metronidazole in at least one other organism [93], its
role in metronidazole resistance in H. pylori is still unknown. However, an in vitro study
showed that thioredoxin protein 1, trxA1, can be an electron donor for AhpC [94]. Finally,
there is also evidence that an efflux pump (TolC) is responsible for metronidazole
resistance. When two of four TolC homologs (HP0605 and HP0971) are mutated, it leads to
an increase in susceptibility to metronidazole even though single-knockout mutants are still
resistant [95]. Taken together, it is clear that rdxA and frxA mutations confer metronidazole
resistance. However, the role of other genes and mutations require more thorough
characterization.
Second Line Therapies and Resistance
Tetracyclines—Tetracyclines are often used as a second line therapy when H. pylori
infections are not cured by the first line drug regimen. The tetracyclines include tetracycline,
chlortetracycline, oxytetracycline, doxycycline, and tigilcycline [6]. Tetracyclines function
by inhibiting bacterial protein synthesis. They do this by binding to the 30S ribosomal
subunit and blocking the attachment of a new aminoacyl-tRNA to the ribosomal acceptor
site [6, 96–98]. This effectively stops synthesis of bacterial peptides. However, since the
interaction between the ribosome and the tetracycline is reversible, the antibiotic has a
bacteriostatic effect [96, 97].
As with other drugs, resistance patterns to tetracyclines vary by geographic distribution:
resistance rates are fairly low (0–7% in some areas) [99, 100], but higher in others (as high
as 59% in China) [101]. Tetracycline resistance in H. pylori was first observed in 1996
[102], and primarily occurs through alteration of nucleotides within the primary tetracycline
binding site [103]. For instance, a triple mutation in the 16S rRNA gene at nucleotides 926–
928, from AGA to TTC, has been shown to confer high level tetracycline resistance and is
found worldwide [103–107]. Additionally, single and double mutations in this region
weaken the interaction of 16S RNA with tetracycline, and result in moderate resistance to
tetracycline [99, 106, 108, 109].
While changes in the 16S rRNA sequence are the primary mechanism of tetracycline
resistance, there are reports of weakly resistant H. pylori strains with no mutations in their
16S rRNA [108, 109]. Moreover, some of these tetracycline resistant strains demonstrate
normal ribosome-tetracycline binding [108]. While the mechanism of resistances in these
strains is unclear, some possible explanations include the presence of efflux pumps or
mutations in various porin genes [109]. Putative efflux systems have been identified in H.
pylori [110]. Although no observable tetracycline efflux activity was initially found [111], a
later study found that the efflux pump, HefABC, actually does show efflux activity for
tetracycline [45]. Additionally, mutations within this pump results in an increase in
susceptibility to tetracycline [45].
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Rescue/Salvage Therapy and Resistance
Fluoroquinolones—Some of the newer weapons used in the war against H. pylori are the
fluoroquinolones. Fluoroquinolones include ciprofloxacin, gatifloxacin, sitafloxacin,
moxifloxacin, temafloxacin, and levofloxacin. Currently, these drugs are used as rescue or
salvage therapy, when both first and second line therapies have failed to eradicate infection.
Fluoroquinolones target topoisomerase II (gyrase) or topoisomerase IV (a gyrase
homologue) activity of bacterial cells [112]. Bacterial gyrases act by making cuts in DNA,
thus allowing the nucleic acid strand to be in a relaxed orientation, where it is available for
replication, recombination, and transcription [6]. Resistance mutations to ciprofloxacin, in
other bacteria has been found in amino acids 67–106 of the gyraseA subunit [113]. Thus,
this region has been deemed the “quinolone resistance determining region,” or the QRDR
[114].
Fluoroquinolone resistance rates vary geographically to as low as 13.8% (Lisbon) [115] to
between 21.5% and 33.8 % (depending on the fluoroquinolone) in Korea [116]. As with
other bacteria, most quinolone resistance mutations in H. pylori are found within the QRDR.
The first amino acid mutations identified were Asn87Lys, Ala88Val, Asp91Gly, Asp91Asn,
Asp91Tyr [116–118], and a double mutation at amino acid Asp91 to a Gly, Asn, or Tyr
combined with either a Ala97Val or Ala97Asn substitution [116, 118]. The Ala97Val
mutation has subsequently been shown not to be associated with resistance when found
alone [119]. Other double mutations identified as being important in fluoroquinolone
resistance are Ala84Pro/Ala88Val and Ser83Ala/Asn87Lys [118]. Miyachi et al. found three
new mutations causing levofloxacin resistance to be Asn87Ile, Asn87Tyr, and a double
mutation of Asn87His and Asp91Gly [120]. Indeed, many studies have confirmed that the
major mutation causing fluoroquinolone resistance occurs in gyrA at position 91 [116, 119,
121] or 87 [118, 120]: studies have shown that 95.7% of gatifloxacin resistant strains [121]
and 83.3% of levofloxacin resistant strains [120] contains mutations at these residues.
Currently, only a single resistant strain has been identified that does not contain a mutation
within the QRDR [118]. This discovery suggests that there are additional mechanisms of
fluoroquinolone resistance in H. pylori. Common mechanisms of resistance found in other
bacteria, such as efflux pumps and topoisomerase IV, appear not to apply here, since there is
evidence that efflux pumps are not a strategy for antimicrobial resistance to
fluoroquinolones in H. pylori [45, 111] and genes such as parC or parE are not found in the
H. pylori genome [119, 122, 123]. Several studies have also looked at gyrB, but no
mutations resulting in resistance were isolated [119–121]. Therefore, currently the
alternative mechanism of resistance remains unknown, and further studies need to be
completed to have a more inclusive understanding of fluoroquinolone resistance.
Rifamycins—Rifamycins, which consists of rifampicin and rifabutin, are used for rescue
therapy. These drugs are bactericidal, due to the irreversible blockage of the DNA-
dependent RNA polymerase [124]. While there are no prevalence studies for resistance to
rifamycins, resistance is possible by mutation within the rpoB gene, which encodes the β-
subunit of RNA polymerase [125]. Several different amino acids substitutions have been
shown to confer rifamycin resistance: Leu525Pro, Gln527Lys [126], Gln527Arg,
Asp530Val [126, 127], Asp530Asn [126], His540Tyr [126, 127], His540Asn [126],
Ser545Leu [126, 127], Ile586Asn, and Ile586Leu [126]. Not surprisingly, these regions are
also important for rifamycin resistance in E. coli and mycobacteria [126]. Other amino acids
substitutions within rpoB that have been shown to be important for rifamycin resistance
include Val149Phe [128, 129] and Arg701His [129].
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Nitrofurans—Nitrofurans are prodrugs that become active when the nitro group is reduced
by an oxygen-insensitive nitroreductase. This activation results in the production of
electrophilic intermediates that cause DNA damage and attack bacterial ribosomal proteins,
thus blocking protein synthesis and causing cell death [130–132]. Nitrofurans consist of
furazolidone and nitrofurantoin. Prevalence of nitrofuran resistance has been shown to be
between 1.6% [133] and 4% [51]. This low resistance rate could be attributable to the fact
that nitrofurans are not widely used.
While the mechanism of action of these drugs are similar to 5-nitroimidazoles, resistance is
not acquired through the same mechanisms. While 5-nitroimidazole (such as metronidazole)
resistance arises from mutations within rdxA and frxA, knockouts of these genes did not
produce resistance to furazolidone or nitrofurantoin [133]. This suggests that the nitrofurans
could be used as an alternative to metronidazole [133].
It has been suggested that activation of the nitrofurans requires two reduction steps such as
is the case in E. coli [131, 133]. Evidence for two reduction steps includes: the fact that in
vitro serial passage does not produce any nitrofuran resistant strains [134] and that despite
the fact that FrxA has the ability to reduce nitrofurans [135], knockouts of frxA do not confer
nitrofuran resistance[133]. Additional nitroreductases suggested as having a role in
nitrofuran resistance in H. pylori are pyruvate::flavodoxin oxidoreductase (PorCDAB) [133,
135] and 2-oxoglutarate oxidoreductase (OorDABC) [133]. When these genes are mutated, a
low-level resistance is conferred to nitrofurans as well as to metronidazole [133]. If
resistance is acquired in a two step mechanism, these antibiotics may be the next good
weapon physicians have against H. pylori.
Alternative treatments methods
Characteristics of H. pylori, such as high colonization rates, longevity of infection, severity
of associated diseases, and the ability to become resistant to varying antibiotics with diverse
mechanisms of action, has led to investigation into alternative treatment methods. These
alternatives include modifying diet or vitamin intake, developing a vaccine for H. pylori,
and modifying existing treatment regimes. Modifications to diet or vitamin intake includes
the addition of vitamin C supplements, which may reduce risk of gastric maladies [136–138]
and H. pylori’s ability to colonize [139, 140], and prostaglandins (either taken directly or
obtained through polyunsaturated fatty acids), which protect the gastric mucosa from
damage [141–143].
Arguably the best option would be the production of a H. pylori vaccine, and several
possible vaccine candidates are being researched [144–146]. Vaccine components vary and
include killed H. pylori whole cell extracts [147], heat shock proteins [148], flagellar
antigens [144], adhesion antigens [149], lipopolysaccharide antigens [150], neutrophil
activating protein [151], and urease [152]. Unfortunately many of these are a long way from
human trials [144–146], and the inactivated whole cell extract were proven ineffective in a
human volunteer study [153].
In lieu of an affective vaccine, many new drugs have shown promise against H. pylori. For
instance, other prodrugs use different primary reductases than metronidazole, providing an
alternative to a drug that is ineffective in many areas [135]. Newer fluoroquinolones
(sitafloxacin, HSR-903, gatifloxacin, Bay 12–8039, and trovafloxacin) [154–156] and new
rifamycins (KRM-1657 and KRM-1648) [157] show in vitro activity against H. pylori at
low concentrations, suggesting that they may be affective in vivo.
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Modifications to current therapeutic regimes include the addition of lactoferrin, which has
been proven to improve eradication rates when used with certain triple therapies [158] and
lactobacillus, which has been proven to lower side effects of some antibiotics thus,
potentially increasing patient compliance [159, 160]. A final possible modification to current
therapeutic regimes is the addition of a metal, such as bismuth or cobalt II, to the treatment
regimes. Bismuth compounds prolong antibiotic use by reducing resistance rates as well as
producing a synergistic effect with several drugs [161, 162]. Cobalt II shows particular
promise, as it is effective at 100 times lower concentrations than bismuth [163]. Along these
lines, since two enzymes essential for colonization, hydrogenase and urease [164–167],
require nickel for maturation [168–174] and there is no clear biochemical function for nickel
in the human host [175], theoretically nickel chelation could be used as an effective
antimicrobial agent.
H. pylori has evolved into a highly antimicrobial resistant pathogen, obtaining resistance to
almost all first, second, and rescue therapy antibiotics. Scientists have been able to identify
many of the molecular mechanisms that confer resistance (Table 2 and Figure 1). However,
there are still some unknown resistance mechanisms to identify. While currently it may
seem as if H. pylori is winning the war against antibiotics, hopefully new treatment options
will improve eradication rate. Overall, it is clear that novel strategies, such as inhibitors of
virulence factors [176], and drug development will be required to produce the tools to allow
physicians to yet win the war against this strategic pathogen.
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Figure 1.
Cellular components targeted by commonly used antibiotics and mechanisms of resistance
utilized by H. pylori. The upper portion of the figure depicts normal drug interactions, while
the lower portion depicts resistance mechanisms currently identified in H. pylori. * Denotes
a mutation in the specified gene. A. β-lactams prevent the completion of the peptidoglycan
layer of H. pylori through their interaction with penicillin binding proteins (PBP). Resistant
bacteria contain either a mutated PBP, which prevents interaction with the β-lactams, or
mutations in hopB or hopC, which decrease accumulation of the β-lactam within the
bacterial cell. B. Nitrofurans and nitroimidizoles act in a similar manner against bacterial
DNA. Both pro-drugs enter the cell and must be reduced by nitroreductases to become
active. The activated form leads to formation of radicals that damage DNA. In resistant
bacteria one or more of these nitroreductases are inactivated. The existence of a TolC efflux
pump has also been identified as a mechanism of resistance to nitroimidizoles. C.
Fluoroquinolones act upon gyrases, which are enzymes responsible for the conversion of
DNA into a relaxed state required for DNA replication. Bacteria containing mutations in
these gyrases are resistant to Fluoroquinolones. D. Rifamycins act by blocking a subunit of
the DNA dependent RNA polymerase thereby terminating the production of mRNA.
Resistant bacteria contain mutations within this subunit, which is encoded by the rpoB gene.
E. Tetracyclines and macrolides both prevent the completion of translation, thereby
preventing protein production. Mutations within specific ribosomal subunits cause H. pylori
to be resistant to these drugs. Also, the HefABC efflux pump has been shown to remove
tetracycline and some macrolides from the bacterial cell.
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Table 2
Specific Antibiotic Resistance Mutations found in H. pylori.
Antibiotic Class Mechanism of resistance Mutation Reference
Macrolides
Mutation of domain V of the 23S rRNA
A2142G [22, 24, 27– 32]
A2142C [33]
A2143G [22, 24, 27– 32]
A2144T [38]
T2182C [37]
G2223A [39]
C2244T [39]
T2288C [39]
Double mutation of A2115G
and G2141A
[29, 41]
T2289C* [39]
Mutation outside domain V of the 23S rRNA T2717C [42]
Unknown Unknown [28, 42]
β-Lactams
Mutation of penicillin/PBP4 complex Unknown [54, 55]
Mutation of PBP1 penicillin binding domain
Ala369Thr [63]
Val374Leu [63]
Glu406Ala [59]
Ser414Arg [58, 63]
Ser417Thr [59]
Leu423Phe [63]
Thr438Met [60]
Met515Ile [59]
Asp535Asn [59]
Ser543Arg [59]
Thr556Ser [59, 63]
Asn562Tyr [59, 63]
Thr593Ala [63]
Gly595Ser [63]
Lys648Gln [59]
Arg649Lys [59]
Arg656Pro [59]
Thr438Met [60]
Mutation of PBP1 and PBP3
PBP1: Ser414Arg, Leu423Phe,
Asn562Try, and Thr593Ala
PBP3: Ala499Val and
Glu536Lys
[65]
Mutation of PBP1, PBP2, and PBP3
PBP1: Ser414Arg, Leu423Phe,
Asn562Try, and Thr593Ala
PBP2: Ala296Val, Asn/
Ser494His, Ala/Val541Met,
[65]
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Antibiotic Class Mechanism of resistance Mutation Reference
and Glu572Gly PBP3:
Ala499Val and Glu536Lys
Decrease membrane permeability
Mutations in Amino Acids
116–201 of hopB
[60]
Stop codon at amino acid 211
of hopC
[60]
Nitroimidazoles
Inactivation of rdxA Various mutations producingtruncated RdxA
[73, 75–82, 177]
Mutation of rdxA
Arg16His [80]
Gln197Lys [80]
Cys19Tyr [77]
Tyr46His [79]
Pro51Leu [79]
Ala67Val [79]
Ala80Thr [80]
Double mutation of Ala80Thr
and Val204Ile
[80]
Inactivation of frxA Various mutations producingtruncated FrxA
[84, 85]
Missense mutations in frxA
Cys161Tyr [85]
Arg206His [85]
Double mutation of
Trp137Arg and Glu164Gly
[85]
Dual inactivation of frxA and rdxA
Various mutations producing
truncated RdxA and FrxA
[77, 84, 85]
Unknown [83]
Dual inactivation of fdxB and rdxA Unknown [83]
Tetracyclines
Mutation of primary tetracycline binding site in16S rRNA
gene
Mutations of Nucleotides
AGA926–928 TTC
[103–107]
Various single and double
mutations of nucleotides 926–
928
[99, 105, 106, 108, 109]
Unknown Unknown [108, 109]
Fluoroquinolones Mutations in gyrA
Asn87Lys [116–118]
Asn87Ile [120]
Asn87Tyr [120]
Ala88Val [116–118]
Asp91Ala [117]
Asp91Asn [116–118]
Asp91Gly [116–118]
Asp91Tyr [116–118]
Double mutation of Ser83Ala
and Asn87Lys
[118].
Double mutation of Ala84Pro
and Ala88Val
[118].
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Antibiotic Class Mechanism of resistance Mutation Reference
Double mutation of Asn87His
and Asp91Gly
[120]
Double mutation of amino acid
Asp91Gly and Ala97Val or
Ala97Asn**
[116, 118]
Double mutation of amino acid
Asp91Asn and Ala97Val or
Ala97Asn**
[116, 118]
Double mutation of amino acid
Asp91Tyr and Ala97Val or
Ala97Asn**
[116, 118]
Unknown Unknown [118]
Rifamycins Mutations in rpoB
Val149Phe [128, 129]
Leu525Pro [126]
Gln527Arg [126, 127]
Gln527Lys [126]
Asp530Asn [126]
Asp530Val [126, 127]
His540Asn [126]
His540Tyr [126, 127]
Ser545Leu [126, 127]
Ile586Asn [126]
Ile586Leu [126]
Arg701His [129]
Nitrofurans Mutation in nitroreductases Mutations in PorCDAB andOorDABC
[133]
*
Indicates that there is controversy over the role of this mutation [40].
**
Indicates that a single mutation at amino acid 97 was not sufficient to confer resistance [119].
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